Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Rituximab is a chimeric anti-CD20 monoclonal B cell–depleting antibody indicated for
certain hematologic malignancies and active rheumatoid arthritis with inadequate response …

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV
lupus nephritis (LN). Methods Patients were randomized 1: 1: 1 to receive placebo, 400 mg …

Aberrant production of autoantibodies by inappropriately self-reactive plasma cells is an
inherent characteristic of autoimmune diseases. Several therapeutic strategies aim to …

Objective A number of open‐label studies have suggested the potential benefit of rituximab
(RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled …

Lupus is a chronic inflammatory autoimmune disease with a wide range of clinical
presentations resulting from its effect on multiple organ systems. There are four main types …

OBJECTIVE: To present a pooled analysis of the efficacy of rituximab from European cohorts
diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab …

Background The treatment of lupus nephritis (LN) remains problematic because the current
treatment regimen based on unspecific immunosuppressants such as steroids …